The findings matter because schizophrenia has long been viewed primarily through the lens of dopamine signaling and abnormal brain development. Yet a growing body of evidence implicates chronic low-grade inflammation as a contributing factor, and immune signaling pathways have emerged as promising targets for understanding — and perhaps eventually treating — aspects of the illness that antipsychotic medications leave untouched. The IL-33/sST2 axis sits at a particularly interesting junction within that landscape, because it connects immune alarm signaling directly to both neural tissue and metabolic regulation.

IL-33 itself is a fascinating molecule. Often described as an “alarmin,” it is normally stored inside the nuclei of endothelial cells, epithelial cells and other structural tissues, and it is released when cells are damaged or stressed. Once outside the cell, IL-33 acts as a damage-associated molecular pattern — a DAMP in immunological shorthand — alerting the immune system to tissue injury. It exerts its effects by binding to a receptor called suppression of tumorigenicity-2, or ST2, which sits on the surface of immune cells, mast cells, and even neurons and glia. The brain is richly endowed with IL-33 and ST2 expression, particularly in astrocytes and microglia, the resident immune cells of the central nervous system, which has fueled speculation that dysregulated IL-33 signaling could contribute to the neuroinflammatory component of psychiatric disease.

There is a twist in the receptor biology that makes measuring this system tricky. The ST2 gene produces two major isoforms: a membrane-bound form that transmits signals into the cell, and a soluble decoy form, sST2, that floats freely in the blood and mops up IL-33 before it can bind its functional receptor. In other words, sST2 acts as a natural brake on IL-33 activity. When researchers measure both molecules in serum, the ratio between them offers a rough gauge of the balance between immune alarm signaling and its suppression. The new study examined exactly this balance in 39 patients with schizophrenia, 24 of their healthy siblings, and 25 unrelated healthy controls — a design that allows investigators to ask whether immune alterations are tied to the illness itself or to shared genetic and familial vulnerability.

Serum concentrations of IL-33 and sST2 were quantified using enzyme-linked immunosorbent assay, the workhorse technique of protein biomarker research, alongside a battery of metabolic measurements including waist circumference, blood pressure, fasting glucose, and lipid profiles. Cognitive performance was assessed using well-validated neuropsychological instruments, notably the Trail Making Test, which probes executive function and processing speed, while social and occupational functioning was rated with the Personal and Social Performance Scale. Symptom severity was measured with the Positive and Negative Syndrome Scale, and metabolic syndrome was defined by standard clinical criteria.

The headline result is a clear immune signature: patients with schizophrenia showed elevated IL-33 and reduced sST2 relative to healthy controls, a pattern consistent with heightened and insufficiently counteracted alarmin signaling. Intriguingly, the healthy siblings of patients — who share roughly half their genes with their ill relatives but do not have the diagnosis — showed IL-33 levels similar to controls rather than to patients. That pattern suggests the IL-33 elevation may be more closely tied to the illness state or its treatment than to inherited familial risk alone, though the authors are careful to note that the sibling subgroup was small and the result should be interpreted with caution. sST2 levels in siblings did not differ significantly from either the patient or control groups.

When the team explored how these immune markers relate to the clinical realities of schizophrenia, the picture became more nuanced. The IL-33/sST2 axis was associated with metabolic syndrome, the dangerous cluster of abdominal obesity, hypertension, dyslipidemia and insulin resistance that affects a large proportion of people with schizophrenia and dramatically shortens their life expectancy through cardiovascular disease. The markers also correlated with social functioning, the capacity to maintain relationships, work, and independent daily life that most strongly predicts long-term quality of life in this population. But when it came to the cognitive domain, the story changed: neither IL-33, nor sST2, nor their ratio showed significant correlations with executive function or processing speed, and metabolic parameters likewise showed no association with neurocognitive test performance.

This dissociation is scientifically telling. Cognitive impairments in schizophrenia are considered core features of the illness, tightly linked to neurodevelopment, and often present before the onset of psychosis. If the IL-33/sST2 axis tracks metabolic and functional outcomes but not cognition, it may be marking a distinct pathological pathway — one involving peripheral inflammation and metabolic dysregulation — rather than the neurodevelopmental processes that drive cognitive deficits. That distinction could matter enormously for future therapeutic strategies. Anti-inflammatory or immunomodulatory interventions might, for example, improve metabolic health and social outcomes in schizophrenia without being expected to rescue cognitive performance, and biomarkers like sST2 could eventually help identify which patients would benefit most.

The researchers also used receiver operating characteristic analysis to explore whether IL-33 or sST2 could serve as diagnostic cut-offs capable of distinguishing patients from controls. While the analysis yielded cut-off values with measurable discriminatory power, the authors are explicit that these findings do not support clinical use. The study is cross-sectional, meaning it captures a single moment in time and cannot establish whether immune changes precede or follow the illness and its treatments. The sample is small, particularly the sibling group, and the authors acknowledge in their conclusions that the exploratory nature of the work, the limited cohort size, and the absence of longitudinal data mean IL-33 and sST2 cannot yet be considered diagnostic or prognostic biomarkers for schizophrenia.

Those caveats are standard scientific humility, but they do not erase the study’s contribution. Replicated elevations of IL-33 with compensatory failure of its soluble decoy receptor would strengthen the case that alarmin signaling is a genuine player in schizophrenia biology, connecting the immune system, adipose tissue, and the social difficulties that define real-world disability in the disorder. Larger prospective cohorts, ideally following patients from illness onset and including first-episode and drug-naive participants to disentangle medication effects, are the necessary next step. For now, the study adds an intriguing new thread to the growing tapestry of psycho-immunology: the alarm signals of a stressed immune system may echo far beyond inflammation, shaping metabolism and the fabric of social life in people living with schizophrenia.

Subject of Research: The association of serum IL-33 and sST2 immune markers with metabolic syndrome, social functioning, and cognition in schizophrenia.

Article Title: IL-33/sST2 axis is associated with metabolic syndrome and social functioning, but not executive function or processing speed, in schizophrenia

Article References: IL-33/sST2 axis is associated with metabolic syndrome and social functioning, but not executive function or processing speed, in schizophrenia. (n.d.). https://doi.org/10.1186/s12888-026-08414-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08414-1

Keywords: schizophrenia, IL-33, sST2, inflammation, biomarkers, metabolic syndrome, social functioning, executive function, processing speed, immune system, psychiatry, alarmins